Optimer (OPTR) (REGN) (LAVA) (LNKD) (LVS) (MRX) Ratings Reiterated

Optimer Pharmaceuticals (NASDAQ: OPTR), Regeneron Pharma (NASDAQ: REGN), Magma Design Automation (NASDAQ: LAVA), Linkedin Co. (NASDAQ: LNKD), Las Vegas Sands Corp. (NYSE: LVS) and Medicis Pharmaceuticals (NYSE: MRX) had ratings on them reiterated by analysts.

Canaccord Genuity reiterated its "Buy" rating on Optimer Pharmaceuticals (OPTR).

Leerink Swann reiterated its "Outperform" rating on Regeneron Pharma (REGN).

Needham & Company reiterated its "Buy" rating on Magma Design Automation (LAVA).

Bank of America (NYSE:BAC) reiterated its "Buy" rating on Linkedin Co. (LNKD). They have a price target of $92.00 on the company.

Nomura reiterated its "Buy" rating on Las Vegas Sands Corp. (LVS).

Canaccord Genuity reiterated its "Buy" rating on Medicis Pharmaceuticals (MRX).